Australia markets closed

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
480.73+1.70 (+0.35%)
At close: 04:00PM EDT
480.60 -0.13 (-0.03%)
After hours: 06:56PM EDT

Vertex Pharmaceuticals Incorporated

50 Northern Avenue
Boston, MA 02210
United States
617 341 6100
https://www.vrtx.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees5,400

Key executives

NameTitlePayExercisedYear born
Dr. Jeffrey Marc Leiden M.D., Ph.D.Executive Chairman95.02kN/A1956
Dr. Reshma Kewalramani FASN, M.D.CEO, President & Director5.59M3.86M1973
Mr. Charles F. Wagner Jr.Executive VP & CFO2.12MN/A1968
Mr. Stuart A. Arbuckle B.Sc.Executive VP & COO2.76M3.21M1966
Dr. David M. Altshuler M.D., Ph.D.Executive VP & Chief Scientific Officer2.17M154.49k1965
Ms. Kristen C. Ambrose CPASenior VP & Chief Accounting OfficerN/AN/A1977
Mr. Mike TirozziSVP and Chief Information & Data OfficerN/AN/AN/A
Susie LisaSenior Vice President of Investor RelationsN/AN/AN/A
Mr. Jonathan Biller J.D.Executive VP & Chief Legal OfficerN/AN/A1964
Ms. Nina DevlinSenior VP & Chief Communications OfficerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Corporate governance

Vertex Pharmaceuticals Incorporated’s ISS governance QualityScore as of 1 June 2024 is 8. The pillar scores are Audit: 9; Board: 6; Shareholder rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.